AlphaCrest Capital Management LLC lessened its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON – Get Rating) by 44.8% in the third quarter, according to its most recent filing with the SEC. The firm owned 6,131 shares of the biotechnology company’s stock after selling 4,971 shares during the quarter. AlphaCrest Capital Management LLC’s holdings in Axon Enterprise were worth $710,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Capital International Investors lifted its holdings in Axon Enterprise by 605.2% in the first quarter. Capital International Investors now owns 2,660,634 shares of the biotechnology company’s stock worth $366,449,000 after purchasing an additional 2,283,343 shares during the period. William Blair Investment Management LLC lifted its stake in shares of Axon Enterprise by 22.2% in the 2nd quarter. William Blair Investment Management LLC now owns 2,130,903 shares of the biotechnology company’s stock worth $198,536,000 after acquiring an additional 386,861 shares during the period. State Street Corp boosted its holdings in shares of Axon Enterprise by 13.3% in the first quarter. State Street Corp now owns 2,220,692 shares of the biotechnology company’s stock valued at $305,856,000 after acquiring an additional 261,508 shares in the last quarter. Allianz Asset Management GmbH boosted its holdings in shares of Axon Enterprise by 125.9% in the second quarter. Allianz Asset Management GmbH now owns 243,466 shares of the biotechnology company’s stock valued at $22,683,000 after acquiring an additional 135,696 shares in the last quarter. Finally, Sei Investments Co. increased its stake in shares of Axon Enterprise by 586.5% during the second quarter. Sei Investments Co. now owns 147,653 shares of the biotechnology company’s stock valued at $13,757,000 after acquiring an additional 126,144 shares during the period. 75.62% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other news, President Luke Larson sold 3,711 shares of the stock in a transaction on Tuesday, December 27th. The stock was sold at an average price of $168.73, for a total value of $626,157.03. Following the completion of the sale, the president now owns 272,917 shares in the company, valued at $46,049,285.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, President Luke Larson sold 3,711 shares of the company’s stock in a transaction on Tuesday, December 27th. The stock was sold at an average price of $168.73, for a total transaction of $626,157.03. Following the transaction, the president now directly owns 272,917 shares of the company’s stock, valued at $46,049,285.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Patrick W. Smith sold 71,499 shares of the firm’s stock in a transaction dated Tuesday, January 17th. The stock was sold at an average price of $185.77, for a total value of $13,282,369.23. Following the sale, the chief executive officer now owns 2,254,734 shares of the company’s stock, valued at $418,861,935.18. The disclosure for this sale can be found here. In the last three months, insiders have sold 343,342 shares of company stock worth $64,743,588. Corporate insiders own 6.90% of the company’s stock.
Axon Enterprise Stock Performance
Analyst Upgrades and Downgrades
AXON has been the subject of a number of research analyst reports. JPMorgan Chase & Co. downgraded Axon Enterprise from an “overweight” rating to a “neutral” rating and set a $224.00 target price for the company. in a research report on Thursday, March 2nd. Northland Securities upped their price objective on Axon Enterprise from $140.00 to $160.00 in a report on Wednesday, November 9th. Raymond James lowered Axon Enterprise from a “strong-buy” rating to an “outperform” rating and set a $223.00 target price on the stock. in a report on Friday, February 17th. Craig Hallum boosted their price target on shares of Axon Enterprise from $215.00 to $242.00 in a research report on Wednesday, March 1st. Finally, Morgan Stanley raised their price objective on shares of Axon Enterprise from $130.00 to $155.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 13th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $217.50.
About Axon Enterprise
Axon Enterprise, Inc engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services.
Featured Stories
- Get a free copy of the StockNews.com research report on Axon Enterprise (AXON)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON – Get Rating).
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.
